Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

OXAZEPAM

All products: general benefit

Other products in the same Health Canada class (N05BA) — coverage varies; not interchangeable

  • Alprazolam (Xanax): general benefit, Not a benefit
  • Bromazepam (Lectopam): general benefit, Not a benefit
  • Chlordiazepoxide (Librium): general benefit, Not a benefit
  • Clorazepate dipotassium (Tranxene): general benefit, Not a benefit
  • Diazepam (Diazepam Injection USP): general benefit, Limited Use 481, Not a benefit
  • Lorazepam (Apo-Lorazepam): general benefit, Not a benefit

1 more in the class list below

Apo-Oxazepam · DIN 00402737 · 30mg · tablet

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Oxazepam · DIN 00402737 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 1979-12-31 · brand APO-OXAZEPAM · ATC N05BA04 OXAZEPAM · form Tablet · route Oral · ingredients OXAZEPAM 30 MG · company Apotex inc · schedule Targeted substances (cdsa iv)
Check this DIN again · Health Canada product record

Apo-Oxazepam: Formulary list price $0.0750/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0750 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3464 · Verify on the e-Formulary ↗ (DIN 00402737)

Source record
DIN 00402737: Apo-Oxazepam Raw flags: sec3=Y Item: 281608050; group id 499; item number 1293; lccId None; manufacturer id APX Source form: Tab; strength: 30mg Recorded listing: General benefit Source prices (unrounded): $0.0750; ministry $0.0750 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00402737 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3464
Interchangeable products
Serax · DIN 02043688 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

ALPRAZOLAM

· 12 products · General benefit (6), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 0.25mg, 0.5mg, 1mg, 2mg · Tab

BROMAZEPAM

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 1.5mg, 3mg, 6mg · Tab

CHLORDIAZEPOXIDE

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 25mg · Cap

CLORAZEPATE DIPOTASSIUM

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 3.75mg, 7.5mg, 15mg · Cap

DIAZEPAM

· 10 products · Limited Use, codes 481 (1), General benefit (6), Listed, not a benefit (3) · strengths: 5mg/mL, 10mg/2mL, 15mg/3mL, 2mg, 5mg, 10mg · Inj Sol (Preservative Free), Rect Gel-2x 5mg Pk, Rect Gel-2x10mg Pk, Rect Gel-2x15mg Pk, Tab

LORAZEPAM

· 12 products · General benefit (9), Listed, not a benefit (3) · strengths: 0.5mg, 1mg, 2mg · Tab

HYDROXYZINE HCL

· 8 products · Listed, not a benefit · strengths: 10mg, 25mg, 50mg · Cap

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: anxiety neurosis
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. LORAZEPAM · General benefit (9), Listed, not a benefit (4), Limited Use, codes 481 (2), Off-Formulary Interchangeable, not an ODB benefit (6) 1 INDICATIONS TEVA-LORAZEPAM (lorazepam) is indicated for: • the short-term relief of manifestations of excessive anxiety in patients with anxiety neurosis. PM: https://pdf.hres.ca/dpd_pm/00070208.PDF; date March 05, 1985; DIN 00637742; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS APO-OXAZEPAM (oxazepam tablets) is indicated for the short-term symptomatic relief of excessive anxiety and tension in patients with anxiety neurosis. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. APO-OXAZEPAM also is indicated for relieving the symptoms of acute alcoholic withdrawal, including acute agitation and impending delirium tremens. 1.1 Pediatrics Pediatrics (<18 years of age): APO-OXAZEPAM is contraindicated in infants (see 2 CONTRAINDICATIONS). No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (>65 years of age): Evidence from clinical studies and experiences suggests that use in the geriatric population is associated with differences in safety or effectiveness. Long-term use of APO-OXAZEPAM should be avoided in elderly patients. Enhanced monitoring is recommended (see 4.1 Dosing considerations; 7 WARNING AND PRECAUTIONS, Falls and Fractures). https://pdf.hres.ca/dpd_pm/00072522.PDF PM date: SEP 05, 2023 Source product: APO-OXAZEPAM; DIN 00402680; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.